Phase 2 N=54 Pilot Efficacy and Safety Study of AQX-1125 in Atopic Dermatitis
Atopic Dermatitis
Primary: Change From Baseline in Total Lesion Symptom Score (TLSS) — 6.3; 6.6; -1.9; -1.9 units on a scale — p=0.636
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=59 A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis With Hunner's Lesions
Cystitis, Interstitial · Ulcer
Primary: Change From Baseline in the Daily Average Bladder Pain Numeric Rating Scale (NRS) — -1.6; -2.7; -2.5 score on a scale — p=0.142
Phase 2 N=11 Efficacy and Safety of Pregabalin in Treatment of Neuropathic Pain in Patients With Idiopathic Small Fiber Neuropathy
Idiopathic Small Fiber Neuropathy
Primary: Visual Analogue Score for Pain Intensity. — 7.1; 6.9; 7.3; 5.4 score on visual analogue score
Phase 2 N=94 Neurosteroids as Novel Therapeutic Agents for Chronic Pain in OEF/OIF Veterans
Lower Back Pain
Primary: Change in Pain Intensity Rating (Visit 6-Baseline) — 4.11; 4.67 units on a scale — p=0.02
Phase 2 N=302 Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema
Diabetic Macular Edema
Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 12 — 6.8; 8.5; 8.8…
Phase 2 N=63 A Proof of Concept Study Comparing Three Doses of an Oral Solution of LEO 22811 With a Placebo Oral Solution for the Treatment of Psoriasis Vulgaris
Psoriasis Vulgaris
Primary: Percentage Change in Psoriasis Area and Severity Index (PASI) — -5.6; -7.6; -0.3; -12.7 percentage of change in PASI index score — p=0.89
Phase 2 N=30 Study of the Abuse Liability of Oxycodone HCl/Niacin in Subjects With a History of Opioid Abuse
Opioid Abuse
Primary: Drug Like/Dislike Effect at 30 Minutes Post Dose (E 30 Min) — 11.7; 14.7 score on a scale
Phase 2 N=16 Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.
Metastatic Castration-resistant Prostate Cancer
Primary: Part A: Percentage of Patients Experiencing Adverse Events (AEs) — 66.7; 46.2; 33.3; 7.7 Percentage of patients
Phase 2 N=60 A Proof of Concept Study of Intravenous Sodium Nitroprusside in Adults With Symptomatic Schizophrenia
Schizophrenia
Primary: Change in Positive and Negative Syndrome Scale (PANSS) - Total Score - Study Phases 1 and 2 — 83.6; 79.8; 77.6; 76.7 units on a scale — p=0.57
Phase 2 N=134 Combined Pharmaco/Behavior Therapy in Adolescent Smokers
Nicotine Dependence · Nicotine Use Disorder
Primary: Biologically-verified 7-day Point Prevalence Smoking Abstinence — 10; 3; 3; 3 participants — p=0.07
Phase 2 N=114 Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
Leukemia, Myeloid, Acute · Myelodysplastic Syndromes
Primary: Correlation of Patient Specific Mutations With Overall Response Rate — 26; 3; 9; 2 Participants — p=0.035
Phase 2 N=52 BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis
Myasthenia Gravis
Primary: Steroid Sparing Effect — 15; 15 Participants — p=0.03
Phase 2 N=104 Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Relapsed or Refractory Chronic Lymphocytic Leukemia
Primary: Number of Participants With Treatment-emergent Adverse Events — 34; 34; 35; 33 Participants
Phase 2 N=12 Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations
Solid Malignancy · Solid Tumor
Primary: Response Rate (RR) — 1 Participants
Phase 2 N=20 Lumacaftor/Ivacaftor Combination Therapy in Subjects With CF Who Have an A455E CFTR Mutation
Cystic Fibrosis
Primary: Absolute Change From Study Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) Through Week 8 — 2.6; 2.7 Percentage of predicted FEV1 — p=0.9277